Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

155.35
+0.77000.50%
Post-market: 155.27-0.0800-0.05%17:21 EDT
Volume:5.80M
Turnover:899.65M
Market Cap:373.78B
PE:17.29
High:155.81
Open:155.50
Low:153.82
Close:154.58
Loading ...

Pharma Stocks Sink After Ouster of Top FDA Vaccine Regulator

Reuters
·
31 Mar

1 Healthcare Stock to Target This Week and 2 to Turn Down

StockStory
·
31 Mar

Jim Cramer on Johnson & Johnson (NYSE:JNJ): Their Spinoff Was Ill-Advised

Insider Monkey
·
29 Mar

Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case

Reuters
·
29 Mar

Johnson & Johnson Unit Ordered to Pay US About $1.64 Billion in HIV Drug Marketing Case

MT Newswires Live
·
29 Mar

JNJ Unit Ordered to Cough Up $1.64B for Illegal Promotion of HIV Drugs

TIPRANKS
·
29 Mar

Press Release: LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Dow Jones
·
28 Mar

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

GlobeNewswire
·
28 Mar

Johnson & Johnson (NYSE:JNJ) Presents Promising Nipocalimab Data At AAN Annual Meeting

Simply Wall St.
·
28 Mar

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Siemens Healthineers AG (OtherSEMHF)

TIPRANKS
·
27 Mar

2 Recession-Proof Dividend Stocks to Buy and Hold

Motley Fool
·
27 Mar

Jefferies profit misses estimates as bond trading, equity underwriting weaken

Reuters
·
27 Mar

AnaptysBio could have positive read from J&J abstracts, says Guggenheim

TIPRANKS
·
27 Mar

Jim Cramer Highlights Johnson & Johnson (JNJ) as a Rare Winner Amid Market Sell-Off

Insider Monkey
·
27 Mar

BRIEF-J&J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib

Reuters
·
27 Mar

Johnson & Johnson Reports Positive Data from Phase 3 Study of Lung Cancer Drug Candidate

MT Newswires Live
·
27 Mar

J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study

TIPRANKS
·
26 Mar

J&J - Median Overall Survival Not yet Reached With Projected Improvement of More Than One Year Versus Osimertinib

THOMSON REUTERS
·
26 Mar

Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib) Outperforms Osimertinib With a Significant and Unprecedented Overall Survival Benefit in Patients With Egfr-Mutated Non-Small Cell Lung Cancer

THOMSON REUTERS
·
26 Mar

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer

PR Newswire
·
26 Mar